<DOC>
	<DOCNO>NCT02532491</DOCNO>
	<brief_summary>This study compare efficacy effectiveness two second-generation antipsychotic ( SGAs ) use society treatment schizophrenia ( Aripiprazole Risperidone ) investigator within assistance program early-stage psychosis individual Community Cantabria , clinical reference treatment disease Spanish Autonomous Community . Patients include prospective naturalistic study , open flexible-doses randomize one two possible pattern treatment include protocol .</brief_summary>
	<brief_title>Effectiveness Second Generation Antipsychotics First Episode Psychosis Patients : 1-year Follow-up</brief_title>
	<detailed_description>At present evidence antipsychotic treatment would choice treat appearance non-affective psychotic disorder . There number second-generation antipsychotic drug proven effective control positive symptom disease carry number variable side effect evidence treatment choice market . Few study try assess adhesion first episode psychosis prolong treatment time . Thus development experimental study compare effectiveness treatment clinical practice high interest clinical psychiatrist . Study set financial support : data present investigation obtain ongoing epidemiological three-year longitudinal intervention program first-episode psychosis ( PAFIP ) conduct outpatient clinic inpatient unit University Hospital Marqu√©s de Valdecilla , Spain . Conforming international standard research ethic , program approve local institutional review board . Patients meet inclusion criterion family provide write informed consent include PAFIP . The Mental Health Services Cantabria provide fund implement program . None pharmaceutical company supply financial support . Study design : flexible-dose study two neuroleptic ( Aripiprazole Risperidone ) assign aleatory ratio 1:1 . Rapid titration schedule ( 5-day ) , optimal dose reach , rule use unless severe side effect occur . At treat physician 's discretion , dose type antipsychotic medication could change base clinical efficacy profile side effect follow-up period . Antimuscarinic medication , Lormetazepam Clonazepam allow clinical reason . No antimuscarinic agent administer prophylactically . Antidepressants ( Sertraline ) mood stabilizer ( lithium ) permit clinically need . Clinical assessment : severity scale Clinical Global Impression ( CGI ) scale , Brief Psychiatric Rating Scale ( BPRS ) , Scale Assessment Positive symptom ( SAPS ) Scale Assessment Negative symptom ( SANS ) use evaluate symptomatology . To assess general adverse event experience Scale Udvalg Kliniske Undersogelser ( UKU ) , Simpson-Angus Rating Scale ( SARS ) Barnes Akathisia Scale ( BAS ) use . The trained psychiatrist ( BC-F ) complete clinical assessment .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Experiencing first episode psychosis ( First Episode Psychosis define psychopathological state first time regardless duration , patient enough severe psychotic symptom allow diagnosis psychosis , receive specific psychiatric treatment ) . Living catchment area ( Cantabria ) . No prior treatment antipsychotic medication , previously treat , total life time adequate antipsychotic treatment le 6 week . Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) criteria brief psychotic disorder , schizophreniform disorder , schizophrenia , schizoaffective disorder . Meeting DSMIV criterion drug dependence . Meeting DSMIV criterion mental retardation . Having history neurological disease head injury loss consciousness .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Psychosis</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Treatment</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Risperidone</keyword>
</DOC>